Segmentation, Size, Key Playersand Regiaa

Pharmaceutical Sterility Testing Market Trends and Growth by Segmentation, Size, Key Playersand Regi

Market Highlights

According to MRFR analysis, the globalPharmaceutical Sterility Testing Market Share isexpected to register a CAGR of 6.10% from 2020 to 2030 and hold a value of USD 900 million by 2030.

Sterility can be defined as the non-appearance ofviable microorganisms, dust, fibers, foreign particles, and other biological agents. Pharmaceutical sterilitytesting is performed on a wide range of biological medicinal products, including blood products, vaccines, biotechnology products, cell products, and tissue products, in accordance with WHO sterilityrequirements. Sterility testing is carried out bycompanies such as pharmaceutical companies, biotechnology companies, and medical devicemanufacturers to assess process control, rawmaterial quality, and product validity.

The industry players focus on technological developments to dominate the global Pharmaceutical Sterility Testing Market research. Inaddition, the key players are involved in new product launches, acquisitions, and joint ventures to augment their market positions. For instance, in July 2020, Neogen Corporation (US) has launched Soleris, an advanced test system that can rapidly detect a wide variety of microorganisms in a fraction of the time.

Key Players

Some of the Pharmaceutical Sterility Testing MarketPlayers are.

- Merck KGaA (Germany),
- Rapid Micro Biosystems (US),
- Sartorius AG (Germany),
- Solvias AG (Switzerland),
- SGS SA (Switzerland),
- Boston Analytical (US),
- bioMérieux, Inc. (France),
- Charles River Laboratories International, Inc. (US),
- Thermo Fisher Scientific, Inc. (US),
- Pace Analytical Services, LLC (US),
- Toxikon, Inc. (US),
- Sotera Health (US),
- Pacific Biolabs Inc. (US),
- STRERIS Corporation (US),
- WuXi AppTec (China).

Regional Analysis

North America is anticipated to dominate the global pharmaceutical sterility testing market outlook, owing to the presence of several key players in the region and the rise in R&D investments by public and private players in the healthcare sector. Moreover, the increase in the number of pipeline products and the launch of advanced drugs based on the biopharmaceutical that requires